Patents by Inventor Giovanni Abbadessa

Giovanni Abbadessa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LUNG CANCER COMBINATION THERAPY WITH IL-2 CONJUGATES AND AN ANTI-PD-1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF
    Publication number: 20230381335
    Abstract: Disclosed herein are methods for treating a lung cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with the anti-PD-1 antibody or antigen-binding fragment thereof (e.g., pembrolizumab).
    Type: Application
    Filed: August 10, 2023
    Publication date: November 30, 2023
    Inventors: Giovanni Abbadessa, Carolina E. Caffaro, Brigitte Demers, Joseph Leveque, Wan-Ju Meng, Jerod Ptacin
  • IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES
    Publication number: 20220016252
    Abstract: Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with an anti-EGFR antibody.
    Type: Application
    Filed: June 24, 2021
    Publication date: January 20, 2022
    Applicant: Synthorx, Inc.
    Inventors: Giovanni ABBADESSA, Carolina E. CAFFARO, Joseph LEVEQUE, Marcos MILLA, Jerod PTACIN, Timothy R. WAGENAAR
  • Combinational compositions and methods for treatment of cancer
    Patent number: 8580764
    Abstract: The present invention provides methods of treating a cell proliferative disorder, such as lung cancer and breast cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound, such as (?)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione, in combination with a therapeutically effective amount of a second anti-proliferative agent, such as gemcitabine.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: November 12, 2013
    Assignee: ArQule, Inc.
    Inventors: Giovanni Abbadessa, Dennis S. France, Chang-Rung Chen, Thomas C. K. Chan
  • Combinational Compositions And Methods For Treatment Of Cancer
    Publication number: 20120004191
    Abstract: The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent.
    Type: Application
    Filed: July 1, 2011
    Publication date: January 5, 2012
    Applicant: ArQule, Inc.
    Inventors: Giovanni Abbadessa, Dennis S. France, Chang-Rung Chen, Thomas C.K. Chan
  • Method for Determining Treatment Efficacy
    Publication number: 20110301194
    Abstract: The present invention provides a method for determining the efficacy of a c-Met inhibitor in treating a cell proliferative disorder, comprising: a) administering to a subject in need thereof a therapeutically effective amount of the c-Met inhibitor, or a pharmaceutically acceptable salt, prodrug or metabolite thereof, either alone or in combination with a therapeutically effective amount of a second anti-proliferative agent; and b) measuring the concentration of hepatocyte growth factor (HGF) in the serum from the subject, wherein if the concentration of serum HGF does not decrease, or if the concentration of serum HGF increases, the c-Met inhibitor is efficacious in treating the cell proliferative disorder.
    Type: Application
    Filed: June 1, 2011
    Publication date: December 8, 2011
    Applicant: ArQule, Inc.
    Inventors: Thomas C.K. Chan, Carol Waghorne, Giovanni Abbadessa